KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Short-Term Debt repayments (2015 - 2017)

Jazz Pharmaceuticals' quarterly Short-Term Debt repayments came in at -$350.0 million in Q4 2017, down 333.33% year-on-year from $150.0 million in Q4 2016, and down 170.0% quarter-over-quarter from $500.0 million in Q3 2017.

Jazz Pharmaceuticals has reported Short-Term Debt repayments for 3 years, with the latest figure at -$350.0 million in Q4 2017.

  • For the quarter ending Q4 2017, Short-Term Debt repayments fell 333.33% year-over-year to -$350.0 million; the trailing twelve-month figure through Sep 2018 stood at -$350.0 million (down 135.0% YoY), and the FY2020 full-year result was $500.0 million, changed N/A from the prior year.
  • Short-Term Debt repayments for Q4 2017 stood at -$350.0 million, down from $500.0 million in the prior quarter.
  • The five-year high for Short-Term Debt repayments was $500.0 million in Q3 2017, with the low at -$350.0 million in Q4 2017.
  • Average Short-Term Debt repayments over 3 years is $121.7 million, with a median of $150.0 million recorded in 2016.
  • Year-over-year, Short-Term Debt repayments jumped 87.5% in 2016 and sank 333.33% in 2017.
  • Tracing JAZZ's Short-Term Debt repayments over 3 years: stood at $80.0 million in 2015, then jumped by 87.5% to $150.0 million in 2016, then plunged by 333.33% to -$350.0 million in 2017.
  • The last three Short-Term Debt repayments figures came in at -$350.0 million (Q4 2017), $500.0 million (Q3 2017), and $200.0 million (Q2 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 102,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Jazz Pharmaceuticals 14.35 Bn 12.51 Bn 934.80 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2017 -350.00 Mn
Dec 31, 2017 -350.00 Mn
Sep 30, 2017 500.00 Mn
Sep 30, 2017 500.00 Mn
Jun 30, 2017 200.00 Mn
Jun 30, 2017 200.00 Mn
Mar 31, 2017 150.00 Mn
Mar 31, 2017 150.00 Mn
Dec 31, 2016 150.00 Mn
Dec 31, 2016 150.00 Mn
Dec 31, 2015 80.00 Mn
Dec 31, 2015 80.00 Mn